论文部分内容阅读
目的探讨顺铂联合多西他赛同步放化疗对局部晚期食管胃交界癌患者生存质量的影响。方法局部晚期食管胃交界癌患者94例随机分为两组。在放疗基础上,观察组(48例)采用静脉滴注顺铂25mg/m~2和多西他赛75mg/m~2化疗,对照组(46例)予静脉滴注顺铂25mg/m~2和氟尿嘧啶500mg/m~2化疗。化疗21d为1个疗程,两组均连续用药2个疗程。比较两组治疗前后卡氏(KPS)评分、体质量变化、生活质量(QOL)评分、临床疗效及生存率情况。结果治疗后,观察组KPS评分[(74.68±5.33)分vs.(65.74±6.43)分]和体质量[(70.38±5.02)kg vs.(60.52±1.54)kg]均优于对照组(P<0.01),临床总有效率(93.75%vs.76.09%)、QOL评分[(31.19±6.04)分vs.(24.02±9.62)分]及5年生存率均高于对照组(20.83%vs.6.52%)(P<0.05或P<0.01)。结论与采用顺铂联合氟尿嘧啶同步放化疗比较,采用顺铂联合多西他赛同步放化疗更能提高局部晚期食管胃交界癌患者生存质量。
Objective To investigate the effect of cisplatin and docetaxel concurrent chemoradiotherapy on the quality of life of patients with locally advanced esophageal cancer. Methods 94 patients with locally advanced esophageal and gastric cancer were randomly divided into two groups. On the basis of radiotherapy, the observation group (48 cases) received intravenous cisplatin 25 mg / m ~ 2 and docetaxel 75 mg / m ~ 2 chemotherapy, while the control group (46 cases) received intravenous cisplatin 25 mg / 2 and fluorouracil 500mg / m ~ 2 chemotherapy. Chemotherapy 21d for a course of treatment, two groups were treated with 2 courses. The KPS score, body mass change, quality of life (QOL) score, clinical efficacy and survival rate were compared between the two groups before and after treatment. Results After treatment, KPS score in the observation group was significantly higher than that in the control group [(74.68 ± 5.33) vs (65.74 ± 6.43) and body weight [(70.38 ± 5.02) kg vs. (60.52 ± 1.54) kg] (P <0.01). The total effective rate (93.75% vs. 76.09%), QOL score [(31.19 ± 6.04) pts vs (24.02 ± 9.62) pts) and 5 year survival rate were significantly higher than those in the control group (20.83% vs. 6.52%) (P <0.05 or P <0.01). Conclusions Compared with cisplatin plus fluorouracil concurrent chemoradiotherapy, cisplatin plus docetaxel concurrent chemoradiotherapy can improve the quality of life of patients with locally advanced esophageal and gastric cancer.